Skip to content

ACER THERAPEUTICS INC.: 10-K filed 2014-02-27

What ACER THERAPEUTICS INC. reported in its annual report filed 2014-02-27 (fiscal FY 2013): 29 published measures, 87 facts as tagged in accession 0001157523-14-000869.

This filing

Form
10-K (annual report)
Filed
2014-02-27
Fiscal period
fiscal FY 2013
Accession
0001157523-14-000869 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACER THERAPEUTICS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-12-3126,239,808USD
At 2012-12-314,146,070USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-12-315,662,534USD
At 2012-12-311,262,738USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-3120,577,274USD
At 2012-12-312,883,332USD
At 2011-12-317,195,364USD
At 2010-12-313,968,713USD
At 2009-12-317,375,148USD
At 2008-12-311,487,397USD
At 2007-12-312,133,585USD
At 2006-12-317,422,898USD
At 2005-12-31-5,580,034USD
At 2004-12-31-3,228,942USD
At 2003-12-31-68,968USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-12-3123,644,542USD
At 2012-12-31592,004USD
At 2011-12-317,109,215USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-16,656,325USD365
2003-01-23 to 2013-12-31-126,267,945USD3996
2012-01-01 to 2012-12-31-8,930,833USD366
2011-01-01 to 2011-12-31-5,968,448USD365
2010-01-01 to 2010-12-31-5,469,067USD365
2009-01-01 to 2009-12-31-1,433,922USD365
2008-01-01 to 2008-12-31-11,852,152USD366
2007-01-01 to 2007-12-31-14,667,367USD365
2006-01-01 to 2006-12-31-12,649,170USD365
2005-01-01 to 2005-12-31-14,856,724USD365
2004-01-01 to 2004-12-31-31,411,736USD366
2003-01-23 to 2003-12-31-126,003USD343

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-6,125,269USD365
2003-01-23 to 2013-12-31-65,560,596USD3996
2012-01-01 to 2012-12-31-8,923,639USD366

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-12-31259,224USD365
2003-01-23 to 2013-12-312,481,423USD3996
2012-01-01 to 2012-12-31550,389USD366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-12-3128,437,031USD365
2003-01-23 to 2013-12-3191,686,561USD3996
2012-01-01 to 2012-12-313,956,817USD366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-12-31740,776USD365
2003-01-23 to 2013-12-31-2,481,423USD3996
2012-01-01 to 2012-12-31-1,550,389USD366

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-12-311,295,024USD
At 2012-12-311,265,041USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-12-311,129,640USD365
2003-01-23 to 2013-12-3117,395,573USD3996
2012-01-01 to 2012-12-31690,726USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-11,923,006USD365
2003-01-23 to 2013-12-31-120,701,476USD3996
2012-01-01 to 2012-12-31-9,133,791USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-12-3124,767,118USD
At 2012-12-311,669,550USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-01-01 to 2013-12-312,267,302USD365
2003-01-23 to 2013-12-3111,674,561USD3996
2012-01-01 to 2012-12-31350,300USD366

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-12-313,324,493USD
At 2012-12-31885,975USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-12-31696,155USD
At 2012-12-31412,096USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2003-01-23 to 2013-12-31325USD3996

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-01-01 to 2013-12-319,181,090USD365
2003-01-23 to 2013-12-3185,678,441USD3996
2012-01-01 to 2012-12-316,318,476USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-12-3127,546,058shares
At 2012-12-316,249,369shares
At 2012-12-145,900,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-12-31146,569,758USD
At 2012-12-31112,432,458USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2012-12-31318,658USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2013-12-313,013,501USD
At 2012-12-312,759,551USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2013-12-311,718,477USD
At 2012-12-311,494,510USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2013-12-31177,666USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-12-311,232,990USD
At 2012-12-31473,879USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-12-313,670,769USD365
2003-01-23 to 2013-12-3133,788,385USD3996
2012-01-01 to 2012-12-312,508,541USD366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-01-01 to 2013-12-31335,597USD365
2003-01-23 to 2013-12-311,985,755USD3996
2012-01-01 to 2012-12-31303,677USD366

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2013-01-01 to 2013-12-3137,910USD365
2003-01-23 to 2013-12-31699,056USD3996

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-12-31147,923USD365
2003-01-23 to 2013-12-31-12,728USD3996
2012-01-01 to 2012-12-31-71,410USD366

Inspect the source

Entity
ACER THERAPEUTICS INC. / CIK 0001069308
Captured
SEC response SHA-256
d41ecd9c66d537efeeb403c8604fe32734f808b5d83b00a9acc9f0ba72164b38

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001069308.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))